- No file added yet -
Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19
journal contribution
submitted on 2023-03-15, 08:00 and posted on 2023-03-16, 06:18 authored by Mohamad Y. Khatib, Karimulla S. Shaik, Amna A. Ahmed, Mohammad A. Alwraidat, Ahmed S. Mohamed, Mohamad R. Abou Kamar, Mouhammad Z. Sharaf Eldean, Bashar K. Aldaraiseh, Abdulqadir J. NashwanThe authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.
Other Information
Published in: Clinical Case Reports
License: http://creativecommons.org/licenses/by/4.0/
See article on publisher's website: http://dx.doi.org/10.1002/ccr3.3487
History
Language
- English
Publisher
WileyPublication Year
- 2020
Institution affiliated with
- Hamad Medical Corporation
